Safety and Immunogenicity of SIIPL Tdap, a New Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, in Healthy Subjects 4–65 Years of Age: A Phase II/III Randomized, Observer-Blinded, Active Controlled, Multicenter Clinical Study in Germany